ProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology Programs
08 mai 2023 08h30 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, May 08, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced that Dr. Matthew Halpert has been...
ProPhase Labs to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 11, 2023 at 11:00 a.m. Eastern Time
04 mai 2023 08h30 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, May 04, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, will hold a conference call on Thursday, May 11,...
ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers
03 mai 2023 08h30 HE
|
ProPhase Labs, Inc.
Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its...
ProPhase Labs CEO Ted Karkus Named One of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023
28 avr. 2023 08h30 HE
|
ProPhase Labs, Inc.
Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted...
ProPhase Labs Announces Launch of Redesigned Corporate Website
25 avr. 2023 08h30 HE
|
ProPhase Labs, Inc.
Garden City, NY, April 25, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today announced the launch of its...
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023
18 avr. 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, April 18, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified biotech, genomics and diagnostics company, today announced that it will be...
ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022
28 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
Company highlights key strategic initiatives to grow underlying value in 2023 and beyond Company announces it is in strategic discussions to develop BE-Smart cancer test globally Company to hold a...
ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time
21 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, March 21, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on...
ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test
07 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
Company Provides Update on Significant Progress at Nebula Genomics Subsidiary Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented...
ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
01 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
Company Outlines BE-Smart Test Roadmap for Commercialization in the U.S. Company in Early Stages of Exploring Development for Commercialization in Other Countries Garden City, NY, March 01,...